Lantern Pharma director buys stock and warrants
Lantern Pharma Inc. director Jeffrey D. Keyser reported buying common stock and warrants.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Lantern Pharma Inc. director Jeffrey D. Keyser reported buying common stock and warrants. He acquired 48,544 shares of common stock in an open-market purchase at $2.06 per share, bringing his direct holdings to 94,303 shares. He also bought 48,544 common stock purchase warrants with an exercise price of $2.27 per share, each for 48,544 underlying shares of common stock. The securities were acquired in the company’s offering of securities that closed on May 14, 2026, and the warrants are exercisable starting November 14, 2026 and expire on November 13, 2031.
Insider Trade Summary
Net Buyer: 97,088 shares
Net Buy
2 txns
Insider
KEYSER D JEFFREY
Role
Director
Bought
97,088 shs ($100K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common stock purchase warrant (Right to Buy) | 48,544 | $0.00 | $0.00 |
| Purchase | Common stock, $0.001 par value | 48,544 | $2.06 | $100K |
Holdings After Transaction:
Common stock purchase warrant (Right to Buy) — 48,544 contracts (Direct);
Common stock, $0.001 par value — 94,303 shares (Direct)
Footnotes (1)
- F1. The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026.
Key Figures
Common shares bought: 48,544 shares
Purchase price: $2.06 per share
Shares owned after: 94,303 shares
+4 more
7 metrics
Common shares bought
48,544 shares
Open-market purchase on May 12, 2026
Purchase price
$2.06 per share
Price paid for common stock
Shares owned after
94,303 shares
Direct common stock holdings post-transaction
Warrants acquired
48,544 warrants
Common stock purchase warrants acquired May 12, 2026
Warrant exercise price
$2.27 per share
Conversion price for underlying common stock
Warrant term
Exercisable 11/14/2026 to 11/13/2031
Warrant exercisability window
Total securities acquired
97,088 securities
Common shares plus warrants in this filing
Key Terms
open-market purchase, common stock purchase warrant, exercise price, offering of securities, +1 more
5 terms
open-market purchase financial
"transaction_action: open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
common stock purchase warrant financial
"Common stock purchase warrant (Right to Buy)"
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
exercise price financial
"conversion_or_exercise_price: 2.2700"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
offering of securities financial
"acquired in the issuer's offering of securities that closed on May 14, 2026"
expiration date financial
"expiration_date: 2031-11-13T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Lantern Pharma (LTRN) director Jeffrey D. Keyser buy?
He bought 48,544 shares of Lantern Pharma common stock and 48,544 common stock purchase warrants. The stock was purchased in an open-market transaction, and the warrants give him the right to buy an additional 48,544 shares at a set price.
At what price did Lantern Pharma (LTRN) stock trade in this insider purchase?
Jeffrey D. Keyser purchased 48,544 Lantern Pharma common shares at $2.06 per share. This open-market transaction increased his direct ownership and was part of a broader securities offering that closed on May 14, 2026, according to the disclosure.
What are the terms of the Lantern Pharma (LTRN) warrants acquired by the director?
The director acquired 48,544 common stock purchase warrants with an exercise price of $2.27 per share. These warrants become exercisable on November 14, 2026 and expire on November 13, 2031, giving a multi-year window to convert them into common shares.
Were the Lantern Pharma (LTRN) securities bought in a public offering or secondary market?
The filing states the reported securities were acquired in Lantern Pharma’s offering of securities that closed on May 14, 2026. This indicates the director participated in the company’s offering rather than only buying shares separately on the open market.
How many total Lantern Pharma (LTRN) securities did the director acquire in this Form 4?
Across both transactions, he acquired 97,088 Lantern Pharma securities: 48,544 shares of common stock and 48,544 common stock purchase warrants. The warrant position represents the right to buy an additional 48,544 common shares at the specified exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
